文献速递炎症性肠病

抗英夫利西单抗抗体浓度可指导失去临床应答的克罗恩病患者治疗强化

Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response.
PubMed 文献 · Aliment Pharmacol Ther · 2017-12-11

本回顾性队列纳入103例英夫利西单抗维持治疗中失去临床应答的克罗恩病患者,比较双倍剂量和/或缩短间隔的治疗强化策略。强化后英夫利西单抗谷浓度从1.2 μg/mL升至3.6 μg/mL(P<.0001),47%患者检出抗英夫利西单抗抗体,抗体可指导治疗强化决策。

要点

  • 治疗强化后63%患者恢复临床应答,42%恢复生物学应答,24%达到生物学缓解。
  • 英夫利西单抗谷浓度从1.2 μg/mL升至3.6 μg/mL(P<.0001),抗体与谷浓度负相关(r -0.57,P<.0001)。
  • 抗体可量化但<282 ng/mL eq.时,联合缩短间隔与双倍剂量恢复谷浓度≥3 μg/mL优于单用双倍剂量,后者优于单用缩短间隔(P<.001)。

核心结论

  • 抗英夫利西单抗抗体可指导克罗恩病患者治疗强化的临床决策。

研究设计与样本

  • 回顾性队列研究,纳入103例英夫利西单抗维持治疗中失去临床应答并接受双倍剂量(10 mg/kg)和/或缩短间隔治疗的克罗恩病患者。

主要发现

  • 治疗强化后63%患者恢复临床应答,42%恢复生物学应答,24%达到生物学缓解(于T+1评估)。
  • 英夫利西单抗谷浓度从T0的1.2 μg/mL [0.3-3.6]升至T+1的3.6 μg/mL [0.5-10.2](P<.0001)。
  • 采用药物耐受检测法,47%患者T0样本检出抗英夫利西单抗抗体。
  • 抗英夫利西单抗抗体与T+1达到的英夫利西单抗谷浓度负相关(Spearman r -0.57,P<.0001),并与T+1临床应答概率相关(P=0.034)。
  • 当T0抗英夫利西单抗抗体可量化但<282 ng/mL eq.时,联合缩短间隔与双倍剂量较单用双倍剂量更有效恢复T+1治疗性谷浓度(≥3 μg/mL),单用双倍剂量又较单用缩短间隔更有效(P<.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The presence of antibodies towards infliximab (ATI) is associated with lower infliximab (IFX) trough concentrations and loss of response. IFX treatment intensification is effective for restoring response in most, but not all patients with Crohn's disease (CD). AIM: To compare outcome, pharmacokinetics and immunogenicity of treatment intensification strategies in patients with CD who lost clinical response to IFX. METHODS: A retrospective cohort study was conducted, including 103 patients with CD who lost clinical response during IFX maintenance therapy and therefore received a double dose IFX (10 mg/kg) and/or a next infusion after a shortened interval. IFX and ATI concentrations were measured in consecutive trough samples, just before (T0) and after (T+1) treatment intensification. RESULTS: Clinical response (physicians' global assessment) and biological response and remission (CRP) were restored in 63%, 42% and 24% of patients (evaluated at T+1). Treatment intensification increased IFX trough concentrations from 1.2 μg/mL [0.3-3.6] at T0 to 3.6 μg/mL [0.5-10.2] at T+1 (P < .0001). Using a drug tolerant assay, ATI were detected in the T0 sample of 47% of patients. ATI negatively impacted the achieved IFX trough concentration (Spearman r -0.57, P < .0001) and the probability of clinical response (P = 0.034) at T+1. When ATI were quantifiable but <282 ng/mL eq. at T0, combined interval shortening and dose doubling was more effective for restoring therapeutic IFX trough concentrations (≥3 μg/mL at T+1) than dose doubling alone, which in turn was more effective than interval shortening alone (P < .001). CONCLUSION: Antibodies towards infliximab can guide clinical decision-making on treatment intensification.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Dreesen E, Van Stappen T, Ballet V, et al. Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response. Aliment Pharmacol Ther. 2017. PMID: 29226370. doi:10.1111/apt.14452

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。